麗珠醫藥(01513.HK):麗珠生物擬3944.57萬元收購麗珠香港100%股權
格隆匯 1 月 27日丨麗珠醫藥(01513.HK)公佈,2021年1月8日,臨時股東大會已批准重組框架協議及其項下擬進行的交易,並授權董事會訂立進一步協議,以使重組框架協議項下擬進行的交易生效。根據該授權,董事會於2021年1月27日批准《關於麗珠生物科技香港有限公司股權轉讓的議案》,以實現重組框架協議項下收購麗珠香港事項("麗珠香港收購事項")。
為實現麗珠香港收購事項,於2021年1月27日,麗珠生物與麗珠開曼簽訂了股權轉讓協議。據此,麗珠開曼同意轉讓而麗珠生物同意收購麗珠香港100%的股權,代價為人民幣3944.57萬元。
麗珠生物應自取得主管發改委及主管商務部門和外管局或其指定銀行就麗珠香港收購事項的備案證明文件之日起20個工作日內或雙方另行協商的時間繳付麗珠香港收購事項的代價。
麗珠香港收購事項的交割應在雙方同意的時間和地點進行,自交割時起,在麗珠生物支付了麗珠香港收購事項的代價的前提下,麗珠生物應對轉讓的股權享有排他的所有權。
麗珠香港收購事項完成後,麗珠香港將由麗珠生物直接持有100.00%。
重組實施還需根據各方後續簽署的相關文件逐步落實和推進,受市場環境變化、監管環境變化或不可抗力等因素影響,後續實施過程中存在一定的不確定性,完成情況取決於工商變更登記、銀行付匯程序、境外減資程序等完成時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.